2025 Recipients of CRI’s Sientific Awards
Cancer Research Institute's 2025 Scientific Awards Recipients
- William B. Coley Award for Distinguished Research in Basic and Tumor Immunology:
- Alan Korman, Ph.D., for his foundational role in developing immune checkpoint inhibitors such as ipilimumab and nivolumab—therapies that have redefined outcomes for patients with advanced cancers.
- Aviv Regev, Ph.D., for pioneering single-cell genomics and computational biology to map immune cell diversity and dynamics, opening new paths for precision immunotherapy.
- Fredrick W. Alt Award for New Discoveries in Immunology:
- Jeffrey Rathmell, Ph.D., for groundbreaking research into immune cell metabolism and its implications for cancer and autoimmune disease.
CRI is pleased to announce the 2025 recipients of our highest scientific honors, the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology, and the Frederick W. Alt Award for New Discoveries in Immunology. Dr. Alan Korman, Chief Scientific Officer of BlueSphere Bio, and Dr. Aviv Regev, Head and Executive Vice President of Genentech Research and Early Development at Genentech, will jointly receive the 2025 Coley Award in recognition of their transformational contributions to immunology. Dr. Jeffrey Rathmell, Chair of the Ben May Department for Cancer Research and Director of the Ludwig Center at the University of Chicago, has been named the recipient of the 2025 Frederick W. Alt Award for New Discoveries in Immunology.
"These extraordinary scientists represent the very best of cancer immunology and immunotherapy," says CRI's CEO, Alicia Zhou, PhD. "Their work is advancing not just our scientific understanding, but our ability to bring real, life-saving solutions to people facing cancer."
More posts featuring Cancer Research Institute.